Tissue Regenix Group PLC TRX BioSurgery wins GPO Supplier Horizon Award
June 21 2018 - 1:10AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
21 June 2018
Tissue Regenix Group plc
TRX BioSurgery recognised at Premier, Inc Breakthrough
Awards
Leeds, 21 June 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
announces that TRX BioSurgery has been awarded the Supplier Horizon
Award by the Group Purchasing Organization, Premier, Inc.
("Premier") at their Breakthrough conference taking place currently
in Nashville, Tennessee.
The Supplier Horizon Award recognizes suppliers that have been
contracted with Premier for less than three years for exceptional
local customer service and engagement, value creation through
clinical excellence and commitment to lower costs. Notably the
awards are voted upon by Premier members who have the first-hand
experience of the products being used in clinical settings.
TRX BioSurgery was originally recognized by the GPO in 2016 when
its' decellularized dermal allograft 'DermaPure' was awarded an
'Innovative Technology Award' by the GPO after a thorough four step
review process determined that the technology offers unique
attributes when compared to the other available treatment
options.
Steve Couldwell, CEO, Tissue Regenix Group commented: "We are
delighted to receive the Premier Horizon award. It again highlights
not only the differentiated clinical outcomes from the use of
DermaPure, but also the health economic advantages of its' single
application in many hospital settings. Being acknowledged by
Premier's member institutions for such an award re affirms our
value proposition in the space, and we look forward to continuing
to establish these relationships."
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Head of Communications 430 3073 /
07920272 441
---------------------------------------- --------------
Jefferies International Ltd Tel: 020 7029
Simon Hardy / Christopher Binks 8000
---------------------------------------- --------------
FTI Consulting Tel: 0203
Brett Pollard / Mo Noonan/ Rob Winder 727 1000
======================================== ==============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGUGDLIXDBGIB
(END) Dow Jones Newswires
June 21, 2018 02:10 ET (06:10 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024